News
Comparative Analysis Highlights Potential Benefits of OncoSil Therapy
Sydney, Australia – 12 January 2026 : OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the publication of a peer- reviewed study in Gastrointestinal Endoscopy titled: “ Combined phosphorus -32 implantation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer: a propensity score –weighted landmark analysis ”.1 The paper was accompanied by an editorial that commented favourably on the analysis.2
The study compared outcomes in patients with locally advanced pancreatic cancer (LAPC) treated with the OncoSil ™ device plus chemotherapy versus chemotherapy alone. The study involved 104 patients overall. Of these, 50 patients received OncoSil ™ in addition to chemotherapy, while 54 patients received chemotherapy alone. After three months of treatment — a key milestone in the study, more patients in the OncoSil ™ treatment group were still being followed and assessed compared with the chemotherapy -only group, highlighting the potential value of adding OncoSil ™ to standard of care.
The analysis was performed by investigators at Royal Adelaide Hospital, South Australia, and Waikato Hospital, New Zealand, and was previously presented at Australian Gastroenterology Week 2024 (AGW 24) in Adelaide by Dr Amanda Lim, an advanced endoscopy fellow at Beth Israel Deaconess Medical Centre, Boston, MA, USA, and an academic researcher from the Royal Adelaide Hospital.
Key findings
The propensity score-weighted landmark analysis demonstrated that combination therapy was associated with:
- Improved overall survival, with an estimated 6.2-month increase in restricted mean survival time within 30 months from initiating treatment compared with chemotherapy alone
- Improved local progression -free survival, with restricted mean survival time within 30 months from chemotherapy initiation estimated to be 168.6 days (5.5 months) longer than for patients treated with chemotherapy alone
- Higher rates of tumour downstaging and surgical resection, with 31.4% of patients receiving OncoSil™ downstaged versus 13.6% with chemotherapy alone, and 28.6% undergoing surgical resection versus 12.1%, respectively and increas ing the probability of downstaging by 23.9%
- A favourable safety profile, with no serious procedure- related adverse events reported
Favourable independent editorial
The study was accompanied by an editorial in Gastrointestinal Endoscopy by Assistant Professor Yen -I Chen, MD, MSc, Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, Québec, Canada. The editorial described the findings as “a signal worth pursuing”, highlighting the strength of the methodology, the magnitude of clinical benefit observed, and the strong safety profile.
Nigel Lange, CEO & Managing Director of OncoSil Medical, said:
“The publication of this study in a leading international journal, together with an independent and favourable editorial, represents an important milestone for OncoSil. The results provide further clinical evidence supporting the potential role of EUS -guided phosphorus -32 therapy in addition to chemotherapy for patients with locally advanced pancreatic cancer and reinforce the rationale for continued clinical development.”
References:
Related articles
Comparative Analysis Highlights
Read more ...
